Treatment of inflammatory skin disorders
a skin disorder and inflammatory technology, applied in the field of skin disorders, can solve the problems of skin atrophy, irritation, dryness in the affected area, increased risk of burns and skin cancer, and increased risk of hypercalcemia, so as to achieve the effect of reducing the risk of skin disorders
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Benefits of technology
Problems solved by technology
Method used
Image
Examples
example 1
Pre-Clinical Trial Establishing the Selective Anti-Apoptotic Activity of APC on Slow Growing, Non Inflammatory Keratinocytes and Psoriasis Skin Keratinocytes
[0135]Six patients with active chronic plaque psoriasis and 6 normal individuals are recruited. They have not received any treatment for at least 4 weeks prior to sampling. Two 6-mm punch biopsies are taken under local anesthetic from the same chronic plaque. Keratinocytes are isolated as we described previously (20).
[0136]Normal keratinocytes are treated with a mixture of cytokines [IL-1α (10 ng / ml), IL-6 (5 ng / ml), TNF-α (5 ng / ml), IL-17A (10 ng / ml)] to induce a psoriatic phenotype. APC is added to keratinocytes at 1, 10 μg / ml and treated for 24, 48 and 72 hrs. Cell proliferation / survival is examined using MTT assay, Brdu proliferation assay. Cell apoptosis is examined by TUNEL assay, Flow cytometry (propidium iodide (PI) or PI plus annexin-V). Cytokine production and four selected psoriasis-associated genes TNF, DEFB4, CAMP, ...
example 2
A Phase 2 Pilot Trial with Subcutaneous APC Over 12 Weeks
[0138]Patient selection: 5 Patients with severe chronic plaque-type psoriasis [Psoriasis Area and Severity Index (PASI) ≧12, body surface area (BSA) ≧10] are enrolled. Primary inclusion criteria includes patients 18 to 70 years of age who have had stable plaque psoriasis for at least 6 months. Primary exclusion criteria includes: i) patients with non-plaque or drug-induced psoriasis; ii) the use of biologicals such as rituximab, abatacept, infliximab, adalimumab, cyclosporine, or mycophenolic acid and etanercept or anakinra within 28 days prior to study iii) patients who have received anti-psoriatic treatment, including any phototherapy, during 8 weeks preceding the study and treatment with any standard topical therapy for psoriasis other than with bland emollients during 4 weeks preceding the study; iv) the use of topical therapy during the study is limited to class III to VII glucocorticoids on the scalp, axillae, and groin ...
example 3
A Phase 2 Pilot Trial with Subcutaneous aPC for Acne Vulgaris in 10 Patients
[0143]Patient selection: 10 Patients with acne vulgaris are enrolled. Primary inclusion criteria includes: patients 18 to 30 years of age who have had bilateral facial acne for at least 6 months. Primary exclusion criteria includes evidence of any active or recent infections, or a history of malignancy or other autoimmune disease, pregnant women.
[0144]Treatment: Patients are administered with 200 ug APC in gel form once a day for 12 weeks or when acne resolves. The patients are provided with two tubes of gel marked L and R and advised to apply 2 cm of gel, squeezed from the tube, to the designated affected area (L on left side of face and R on right side of face) and rub in evenly. Patients are then followed up for an additional 4 weeks after the final treatment.
[0145]Measurement: Photographs are taken before treatment and every 4 weeks and acne area calculated using computer-assisted image analysis. Adverse...
PUM
| Property | Measurement | Unit |
|---|---|---|
| concentration | aaaaa | aaaaa |
| concentration | aaaaa | aaaaa |
| concentration | aaaaa | aaaaa |
Abstract
Description
Claims
Application Information
Login to View More